Michael Landsittel
Net Worth
Last updated:
What is Michael Landsittel net worth?
The estimated net worth of Mr. Michael Landsittel is at least $16,205,850 as of 15 Aug 2024. He owns shares worth $8,700,748 as insider, has earned $4,577,602 from insider trading and has received compensation worth at least $2,927,500 in Blueprint Medicines Corporation.
What is the salary of Michael Landsittel?
Mr. Michael Landsittel salary is $585,500 per year as Chief Financial Officer & Treasurer in Blueprint Medicines Corporation.
How old is Michael Landsittel?
Mr. Michael Landsittel is 53 years old, born in 1972.
What stocks does Michael Landsittel currently own?
As insider, Mr. Michael Landsittel owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Blueprint Medicines Corporation (BPMC) | Chief Financial Officer & Treasurer | 67,208 | $129.46 | $8,700,748 |
What does Blueprint Medicines Corporation do?
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Michael Landsittel insider trading
Blueprint Medicines Corporation
Mr. Michael Landsittel has made 19 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 4,409 units of BPMC stock worth $419,869 on 15 Aug 2024.
The largest trade he's ever made was exercising 28,181 units of BPMC stock on 8 May 2024. As of 15 Aug 2024 he still owns at least 67,208 units of BPMC stock.
Blueprint Medicines key executives
Blueprint Medicines Corporation executives and other stock owners filed with the SEC:
- Dr. Fouad Namouni M.D. (56) Pres of R&D
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Director
- Mr. Jeffrey W. Albers J.D., M.B.A., MBA (54) Chairman, Chief Executive Officer & Pres
- Mr. Michael Landsittel (53) Chief Financial Officer & Treasurer
- Ms. Kathryn Haviland (49) Chief Operating Officer
- Ms. Tracey L. McCain Esq. (57) Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec.